全基因组测序揭示既往异烟肼耐药结核患者的多重耐药来源:纵向队列研究
该纵向队列研究纳入239例异烟肼耐药肺结核患者,随访24个月,用全基因组测序区分多重耐药结核(MDR-TB)是治疗中新发进化还是再感染。14例(5.9%)出现MDR-TB,其中6例(2.5%)为新发进化、6例为再感染,2例结果不确定。研究提示异烟肼耐药结核治疗中需警惕MDR-TB新发,应早期诊断并优化治疗。
要点
- 异烟肼耐药肺结核患者中5.9%出现MDR-TB,新发进化与再感染各占2.5%。
- 全基因组测序可区分MDR-TB为新发进化(≤5 SNPs)或再感染(≥10 SNPs)。
- 异烟肼耐药结核应早期诊断并优化治疗,以防治疗中新发MDR-TB。
核心结论
- 在异烟肼耐药结核中,MDR-TB的新发进化和再感染对MDR发展的贡献相当。
- 亟需对异烟肼耐药结核进行早期诊断和优化治疗,以避免治疗中新发MDR-TB。
研究设计与样本
- 纵向队列研究,招募异烟肼耐药肺结核患者并随访24个月。
- 共纳入239例异烟肼耐药肺结核患者。
- 药敏试验采用显微镜观察药敏试验、分枝杆菌生长指示管和全基因组测序。
- 对MDR-TB诊断者用全基因组测序判断初诊与后续分离株的基因组相关性。
主要发现
- 14/239(5.9%)患者被诊断为第二次发作的MDR-TB。
- 6/239(2.5%)被鉴定为新发进化的MDR-TB,6例为不同菌株再感染。
- 2例基因组距离在5至10个SNPs之间,结果不确定。
关键数值与推荐
- 基因组距离≤5个SNPs假定为新发MDR-TB,≥10个SNPs假定为不同MDR-TB菌株再感染。
- 异烟肼耐药结核患者接受标准一线抗结核治疗时MDR-TB出现风险为8%,药物敏感结核为0.3%(引自Meta分析)。
临床怎么用
- 对异烟肼耐药肺结核患者应早期诊断并优化治疗,以减少治疗中新发MDR-TB。
- 对治疗中出现MDR-TB者,可用全基因组测序区分新发进化与再感染。
局限性
- 2例基因组距离在5至10个SNPs之间,无法判定为新发进化或再感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meta-analysis of patients with isoniazid-resistant tuberculosis (TB) given standard first-line anti-TB treatment indicated an increased risk of multidrug-resistant TB (MDR-TB) emerging (8%), compared to drug-sensitive TB (0.3%). Here we use whole genome sequencing (WGS) to investigate whether treatment of patients with preexisting isoniazid-resistant disease with first-line anti-TB therapy risks selecting for rifampicin resistance, and hence MDR-TB. METHODS: Patients with isoniazid-resistant pulmonary TB were recruited and followed up for 24 months. Drug susceptibility testing was performed by microscopic observation drug susceptibility assay, mycobacterial growth indicator tube, and by WGS on isolates at first presentation and in the case of re-presentation. Where MDR-TB was diagnosed, WGS was used to determine the genomic relatedness between initial and subsequent isolates. De novo emergence of MDR-TB was assumed where the genomic distance was 5 or fewer single-nucleotide polymorphisms (SNPs), whereas reinfection with a different MDR-TB strain was assumed where the distance was 10 or more SNPs. RESULTS: Two hundred thirty-nine patients with isoniazid-resistant pulmonary TB were recruited. Fourteen (14/239 [5.9%]) patients were diagnosed with a second episode of TB that was multidrug resistant. Six (6/239 [2.5%]) were identified as having evolved MDR-TB de novo and 6 as having been reinfected with a different strain. In 2 cases, the genomic distance was between 5 and 10 SNPs and therefore indeterminate. CONCLUSIONS: In isoniazid-resistant TB, de novo emergence and reinfection of MDR-TB strains equally contributed to MDR development. Early diagnosis and optimal treatment of isoniazid-resistant TB are urgently needed to avert the de novo emergence of MDR-TB during treatment.
引用
- Srinivasan V, Ha VTN, Vinh DN, et al. Sources of Multidrug Resistance in Patients With Previous Isoniazid-Resistant Tuberculosis Identified Using Whole Genome Sequencing: A Longitudinal Cohort Study. Clin Infect Dis. 2020. PMID: 32166306. doi:10.1093/cid/ciaa254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。